Published in Expert Opin Ther Targets on November 11, 2015
A capture method based on the VC1 domain reveals new binding properties of the human receptor for advanced glycation end products (RAGE). Redox Biol (2016) 0.89
Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta (2016) 0.83
A model of chronic diabetic polyneuropathy: benefits from intranasal insulin are modified by sex and RAGE deletion. Am J Physiol Endocrinol Metab (2017) 0.75
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol (1993) 3.73
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol (2005) 3.21
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun (2002) 2.88
Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci (2014) 2.80
Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med (2000) 2.79
Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol (2004) 2.54
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med (2009) 2.43
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol (2001) 2.33
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells (2004) 2.03
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (2006) 1.94
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol (2001) 1.89
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79
S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One (2011) 1.63
The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.55
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) (1998) 1.52
Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50
Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am J Respir Crit Care Med (2013) 1.45
The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.45
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes (2006) 1.43
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Formins in cell signaling. Biochim Biophys Acta (2008) 1.39
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis (2004) 1.39
The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des (2008) 1.36
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) (2009) 1.36
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci (2007) 1.32
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 1.30
Soluble forms of RAGE in internal medicine. Intern Emerg Med (2009) 1.28
Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep (2011) 1.28
Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia (2010) 1.26
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens (2005) 1.26
S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res (2011) 1.25
Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res (2010) 1.22
S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem (2011) 1.22
AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging (2010) 1.21
RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J (2009) 1.21
Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis (2011) 1.17
The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem (2010) 1.16
Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci (2013) 1.15
RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One (2010) 1.15
High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Exp Neurol (2011) 1.13
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes (2004) 1.13
The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol (2012) 1.12
RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta (2012) 1.10
Formins as effector proteins of Rho GTPases. Small GTPases (2014) 1.09
RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition. Breast Cancer Res Treat (2013) 1.08
Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res (2008) 1.08
RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res (2014) 1.08
Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med (2012) 1.07
Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem (2010) 1.06
Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des (2008) 1.06
RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes (2014) 1.05
Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes (2015) 1.05
RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res (2009) 1.04
Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem (2011) 1.04
Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity (2014) 0.97
S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest (2001) 0.96
Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci (2008) 0.96
Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell (2010) 0.96
S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res (2013) 0.96
Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res (2012) 0.96
Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun (2011) 0.95
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology (2014) 0.95
S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. PLoS One (2014) 0.95
Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol (2014) 0.94
RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res (2015) 0.94
Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes (2012) 0.93
Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma. Oncotarget (2015) 0.92
Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat (2011) 0.92
Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm (Vienna) (2009) 0.91
AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity (2009) 0.91
Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin (2013) 0.90
Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. PLoS One (2011) 0.89